Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. Jude Medical: Cardiac Rhythm Management Business Has “Turned The Corner”

This article was originally published in The Gray Sheet

Executive Summary

The firm reported during its second-quarter earnings call that its cardiac rhythm management business has stabilized after several quarters of market share decline.

You may also be interested in...



Medtronic, St. Jude Launch New Quadripolar Devices

Medtronic has launched two more Attain Performa left ventricular quadripolar leads for the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators following FDA approval announced Dec. 11. On the same day, St. Jude announced CE mark of the Quadra Allure MP cardiac resynchronization therapy pacemaker, the first quadripolar CRT-P with MultiPoint pacing.

Recalled ICD Leads Can Be Extracted Safely, Cleveland Clinic Study Shows

A 10-year retrospective study from the Cleveland Clinic shows that implantable cardioverter defibrillator leads subject to recalls can be extracted with the same safety and efficacy as non-recalled ICD leads. Another study, published in the same issue of Heart Rhythm, found that younger age and female sex are independent predictors of failure for St. Jude’s Riata lead.

St. Jude First To Market Leadless Pacemaker With Nanostim Buy

St. Jude paid $123.5 million and agreed to up to $65 million in additional milestone payments to acquire Nanostim and its first-in-class leadless pacemaker, which has just earned a CE mark and is expected to launch in select European markets soon.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel